AR068723A1 - Proteina que se une a antigenos que se une a il-23 humana y sus usos - Google Patents

Proteina que se une a antigenos que se une a il-23 humana y sus usos

Info

Publication number
AR068723A1
AR068723A1 ARP080104318A ARP080104318A AR068723A1 AR 068723 A1 AR068723 A1 AR 068723A1 AR P080104318 A ARP080104318 A AR P080104318A AR P080104318 A ARP080104318 A AR P080104318A AR 068723 A1 AR068723 A1 AR 068723A1
Authority
AR
Argentina
Prior art keywords
sec
protein
joins
antigens
human
Prior art date
Application number
ARP080104318A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40378889&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR068723(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR068723A1 publication Critical patent/AR068723A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

También se posee una célula huésped recombinante, una composicion farmacéutica y un procedimiento para tratar un paciente humano que padece inflamacion mediada por el sistema inmunitario tales como artritis reumatoide (RA). Reivindicacion 1: Una proteína que se une a antígenos que se une a IL-23 humana y que comprende la CDRH3 de la SEC. ID. N°: 3, SEC. ID. N°: 4, SEC. ID. N.°: 73, SEC. ID. N.°: 74, SEC. ID. N.°: 95 o SEC. ID. N.°: 100, o sus variantes que contienen 1 o 2 o 3 sustituciones de aminoácidos en CDRH3. Reivindicacion 2: Una proteína que se une a antígenos de acuerdo con la reivindicacion 1, en el que dicha proteína que se une a antígenos comprende las siguientes CDR: CDRH1: SEC. ID. N.°: 1, CDRH2: SEC. ID. N.°: 2, CDRH3: SEC. ID. N.°: 4, CDRL1: SEC. ID. N.°: 5, CDRL2: SEC. ID. N.°: 6, CDRL3: SEC. ID. N.°: 7.
ARP080104318A 2007-10-05 2008-10-02 Proteina que se une a antigenos que se une a il-23 humana y sus usos AR068723A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97784107P 2007-10-05 2007-10-05

Publications (1)

Publication Number Publication Date
AR068723A1 true AR068723A1 (es) 2009-12-02

Family

ID=40378889

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104318A AR068723A1 (es) 2007-10-05 2008-10-02 Proteina que se une a antigenos que se une a il-23 humana y sus usos

Country Status (16)

Country Link
US (2) US20110206686A1 (es)
EP (1) EP2205637A1 (es)
JP (1) JP2011501738A (es)
KR (1) KR20100097654A (es)
CN (1) CN101889026A (es)
AR (1) AR068723A1 (es)
AU (1) AU2008306850A1 (es)
BR (1) BRPI0818620A2 (es)
CA (1) CA2700758A1 (es)
CL (1) CL2008002952A1 (es)
EA (1) EA201000424A1 (es)
MX (1) MX2010003574A (es)
PE (1) PE20091342A1 (es)
TW (1) TW200930729A (es)
WO (1) WO2009043933A1 (es)
ZA (1) ZA201002275B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2064242A1 (en) * 2007-02-23 2009-06-03 Schering Corporation Engineered anti-il-23p19 antibodies
HUE042172T2 (hu) * 2007-02-23 2019-06-28 Merck Sharp & Dohme Genetikailag elõállított anti-il-23P19 antitestek
TWI547287B (zh) 2008-04-25 2016-09-01 戴埃克斯有限公司 Ｆｃ受體結合蛋白
WO2010027766A1 (en) 2008-08-27 2010-03-11 Schering Corporation Lyophilized formulatons of engineered anti-il-23p19 antibodies
JP2012522749A (ja) * 2009-04-01 2012-09-27 グラクソ グループ リミテッド 抗ｉｌ−２３免疫グロブリン
EP2480251A1 (en) 2009-09-21 2012-08-01 Peptinov SAS Carrier conjugates of il-23-peptides and their induced antibodies
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
CA3017116A1 (en) 2010-11-04 2012-05-10 Boehringer Ingelheim International Gmbh Anti-il-23 antibodies
BR112013030352B1 (pt) * 2011-06-02 2020-05-19 Dyax Corp anticorpo anti-fcrn isolado, composição farmacêutica que compreende o dito anticorpo, ácido nucleico isolado, vetor, célula e uso terapêutico do dito anticorpo
ES2908474T3 (es) 2012-05-03 2022-04-29 Boehringer Ingelheim Int Anticuerpos anti-IL-23p19
ES2729603T3 (es) 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
EP3441400B1 (en) * 2012-11-19 2022-07-20 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
CN105188749B (zh) 2012-12-21 2017-12-19 西雅图基因公司 抗ntb‑a抗体及相关组合物和方法
EA201591579A1 (ru) 2013-03-15 2016-01-29 Амген Инк. Способы лечения болезни крона при помощи анти-il-23 антитела
AU2014238148A1 (en) 2013-03-15 2015-10-08 Amgen Inc. Methods for treating psoriasis using an anti-IL-23 antibody
BR112016027024A2 (pt) 2014-05-22 2017-10-31 Pieris Pharmaceuticals Gmbh polipeptídeos de ligação específica e seus usos
EP3708679A1 (en) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
TWI711629B (zh) 2014-09-03 2020-12-01 德商包林格因蓋爾漢國際股份有限公司 靶向IL-23A與TNF-α之化合物及其用途
JP6909208B2 (ja) 2015-09-17 2021-07-28 アムジェン インコーポレイテッド Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
EP3368569B1 (en) 2015-10-30 2021-02-24 Ablynx NV Polypeptides against il-23
KR20180134837A (ko) 2015-12-09 2018-12-19 코버스 파마슈티칼스, 인크. 인간화된 항-cd73 항체
CN108472367A (zh) 2015-12-22 2018-08-31 美国安进公司 作为对il23拮抗剂的临床应答的预测因子的ccl20
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US11845798B2 (en) 2017-05-02 2023-12-19 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
KR20210032441A (ko) 2018-07-13 2021-03-24 아스트라제네카 콜라보레이션 벤처스, 엘엘씨 브라지쿠맙을 이용한 궤양성 대장염의 치료
JP2022551603A (ja) 2019-10-03 2022-12-12 エータイアー ファーマ， インコーポレイテッド 抗ｎｒｐ２抗体を含む組成物および方法
KR20220143005A (ko) 2019-12-20 2022-10-24 노바록 바이오테라퓨틱스 리미티드 항-인터루킨-23 p19 항체 및 이의 사용 방법
CN113698480B (zh) * 2021-09-18 2022-07-01 东大生物技术(苏州)有限公司 一组il-23单克隆抗体及其医药用途
WO2023076998A1 (en) * 2021-10-27 2023-05-04 Atyr Pharma, Inc. COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2a ANTIBODIES
CN114920830B (zh) * 2022-05-07 2023-05-16 北京大学 Vκ4-1-IgLC多肽及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1601694T3 (da) * 2003-03-10 2009-12-14 Schering Corp Anvendelser af IL23-antagonister, relaterede reagenser
TR201902033T4 (tr) * 2005-06-30 2019-03-21 Janssen Biotech Inc Anti-IL-23 antikorları, bileşimleri, yöntemleri ve kullanımları.
EA013506B1 (ru) * 2005-08-25 2010-06-30 Эли Лилли Энд Компани Антитело к il-23 и его применение
US7807160B2 (en) * 2005-08-31 2010-10-05 Schering Corporation Engineered anti-IL-23 antibodies

Also Published As

Publication number Publication date
US20110206686A1 (en) 2011-08-25
US20090123479A1 (en) 2009-05-14
CA2700758A1 (en) 2009-04-09
EP2205637A1 (en) 2010-07-14
WO2009043933A1 (en) 2009-04-09
PE20091342A1 (es) 2009-09-16
CN101889026A (zh) 2010-11-17
EA201000424A1 (ru) 2010-10-29
KR20100097654A (ko) 2010-09-03
ZA201002275B (en) 2011-06-29
AU2008306850A1 (en) 2009-04-09
JP2011501738A (ja) 2011-01-13
CL2008002952A1 (es) 2009-10-16
TW200930729A (en) 2009-07-16
MX2010003574A (es) 2010-04-22
BRPI0818620A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
AR068723A1 (es) Proteina que se une a antigenos que se une a il-23 humana y sus usos
PE20121579A1 (es) Proteinas de enlace al antigeno il-23 humanas
PE20141660A1 (es) PROTEINAS DE UNION A ANTIGENO DE TNF-ALFA CON UNION A FcRn INCREMENTADA
PE20090518A1 (es) Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18)
MX2020013068A (es) Anticuerpo anti proteína reguladora de señales alfa sirpalfana.
JP2020500538A5 (es)
PE20080181A1 (es) Anticuerpos que se unen al peptido beta-amiloide en el tratamiento de alzheimer
AR080698A1 (es) Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
PE20191131A1 (es) Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos
IL299072A (en) Antibodies and methods for using them
HRP20150965T1 (hr) Anti-fgr3 protutijela i metode koje ih koriste
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
AR066164A1 (es) Proteinas humanas de union a antigenos del factor estimulante de colonias de megacariocitos-macrofagos(gm-csf)
RU2588467C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
PE20120554A1 (es) Polipeptidos y metodo de tratamiento
PE20090768A1 (es) Metodos y composiciones para el tratamiento de enfermedades alergicas
PE20080262A1 (es) Anticuerpo humanizado contra interleuquina-18
CL2013003140A1 (es) Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene.
PE20140014A1 (es) Proteinas de union a antigeno contra proproteina converstasa subtilisina/kexina tipo 9 (pcsk9)
AR071891A1 (es) Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
IL259940B2 (en) A method for treating or improving metabolic disorders using gastric inhibitory peptide receptor binding proteins in combination with glucagon-like peptide 1 agonists
UA117294C2 (uk) Імунокон'югат
AR086579A1 (es) Proteinas de union a antigeno
AR081434A1 (es) Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo

Legal Events

Date Code Title Description
FA Abandonment or withdrawal